
Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting.
Topiramate was assessed in an open-label trial as broad-spectrum antiepileptic monotherapy, independently from the epilepsy type or syndrome. Adults and children aged 2 years and older, who were diagnosed with epilepsy within the last 5 years, treatment-naive or failing prior treatment with one antiepileptic drug (AED), received individually adjusted doses of topiramate, after escalation to 100mg/day over 4 weeks (maximum 400mg/day) or 3mg/kg/day over 6 weeks (maximum 9 mg/kg/day), respectively. Patients were followed for >or=7 months and optionally up to a maximum of 13 months. Data were analysed for all patients (n=692), as well as for focal (n=421) and generalized epilepsies (n=148). The median topiramate dose used was 125 mg/day in adults and 3.3mg/kg/day in children (
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Topiramate
- Patient Satisfaction
- Neurology & Neurosurgery
- Middle Aged
- Male
- Infant
- Humans
- Fructose
- Female
- Epilepsy
Citation

Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Topiramate
- Patient Satisfaction
- Neurology & Neurosurgery
- Middle Aged
- Male
- Infant
- Humans
- Fructose
- Female
- Epilepsy